-+ 0.00%
-+ 0.00%
-+ 0.00%

Verastem reports 2-year RAMP 201 data for avutometinib-defactinib combo in recurrent low-grade serous ovarian cancer

PUBT·09/28/2026 20:10:38
Listen to the news
Verastem reports 2-year RAMP 201 data for avutometinib-defactinib combo in recurrent low-grade serous ovarian cancer
  • Verastem highlighted a Gynecologic Oncology publication with two-year follow-up from its Phase 2 RAMP 201 study in recurrent LGSOC.
  • Results were previously presented at the Society of Gynecologic Oncology 2026 annual meeting, then published online ahead of October 2026 print.
  • Follow-up data reinforced durable responses and disease control for the avutometinib-defactinib co-pack across KRAS-mutated and KRAS wild-type patients.
  • Safety and tolerability remained consistent with earlier findings, with no new safety signals reported.
  • Study data supported FDA accelerated approval for treating KRAS-mutated recurrent LGSOC following prior systemic therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609281610BIZWIRE_USPR_____20260928_BW878351) on September 28, 2026, and is solely responsible for the information contained therein.